These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32234758)

  • 1. Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.
    Sokolova AO; Yu EY; Cheng HH
    Clin Cancer Res; 2020 Jun; 26(11):2439-2440. PubMed ID: 32234758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
    Abida W; Campbell D; Patnaik A; Shapiro JD; Sautois B; Vogelzang NJ; Voog EG; Bryce AH; McDermott R; Ricci F; Rowe J; Zhang J; Piulats JM; Fizazi K; Merseburger AS; Higano CS; Krieger LE; Ryan CJ; Feng FY; Simmons AD; Loehr A; Despain D; Dowson M; Green F; Watkins SP; Golsorkhi T; Chowdhury S
    Clin Cancer Res; 2020 Jun; 26(11):2487-2496. PubMed ID: 32086346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
    Varnai R; Sipeky C
    Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
    Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
    Graham LS; Henderson NC; Kellezi O; Hwang C; Barata PC; Bilen MA; Kilari D; Pierro M; Thapa B; Tripathi A; Mo G; Labriola M; Park JJ; Rothstein S; Garje R; Koshkin VS; Patel VG; Dorff T; Armstrong AJ; McKay RR; Alva A; Schweizer MT
    JCO Precis Oncol; 2024 Aug; 8():e2400014. PubMed ID: 39178368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
    [No Abstract]   [Full Text] [Related]  

  • 7. Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
    Rescigno P; Chandler R; de Bono J
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):339-343. PubMed ID: 29979319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
    Sigorski D; Iżycka-Świeszewska E; Bodnar L
    Target Oncol; 2020 Dec; 15(6):709-722. PubMed ID: 33044685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    Bieńkowski M; Tomasik B; Braun M; Jassem J
    Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a
    Sautois B; Loehr A; Watkins SP; Schroeder H; Abida W
    Curr Oncol; 2022 Jun; 29(6):4178-4184. PubMed ID: 35735442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
    Shore N; Ionescu-Ittu R; Yang L; Laliberté F; Mahendran M; Lejeune D; Yu L; Burgents J; Duh MS; Ghate SR
    Future Oncol; 2021 Aug; 17(22):2907-2921. PubMed ID: 33906368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer.
    Akhoundova D; Francica P; Rottenberg S; Rubin MA
    Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring
    Fallah J; Xu J; Joeng HK; Weinstock C; Heiss BL; Maguire WF; Gao X; Cheng J; Chang E; Agrawal S; Fiero MH; Pazdur R; Kluetz PG; Amiri-Kordestani L; Suzman DL
    JCO Precis Oncol; 2024 Aug; 8():e2400354. PubMed ID: 39208375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
    Romero-Laorden N; Piñeiro-Yañez E; Gutierrez-Pecharroman A; Pacheco MI; Calvo E; Al-Shahrour F; Castro E; Olmos D
    Ann Oncol; 2017 May; 28(5):1158-1159. PubMed ID: 28453706
    [No Abstract]   [Full Text] [Related]  

  • 19. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
    Carreira S; Porta N; Arce-Gallego S; Seed G; Llop-Guevara A; Bianchini D; Rescigno P; Paschalis A; Bertan C; Baker C; Goodall J; Miranda S; Riisnaes R; Figueiredo I; Ferreira A; Pereira R; Crespo M; Gurel B; Nava Rodrigues D; Pettitt SJ; Yuan W; Serra V; Rekowski J; Lord CJ; Hall E; Mateo J; de Bono JS
    Cancer Discov; 2021 Nov; 11(11):2812-2827. PubMed ID: 34045297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.